NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 8 - Malignant disease and immunosuppression 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
08.02 Drugs affecting the immune response

Blinatumomab (Blincyto®)
(Intravenous infusion)

RED
Restricted Drug Restricted

Approved in accordance with NICE TA450 and the Cancer Drugs Fund for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia in adults.

Approved in a accordance with NICE TA589 for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity.

BNF BNFc SPC
NICE TA450:Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity NICE TA1049: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia

Pemigatinib (Pemazyre®)
(4.5 mg, 9 mg and 13.5 mg tablets)

RED
Restricted Drug Restricted

RESTRICTED FOR ALL PRESCRIBING - Blueteq or High cost drug form required - see link from Formulary homepage.

For use in accordance with the following NICE TA(s) only:-

BNF BNFc SPC BlueTeq
NICE TA 722 Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
08.02 Immunosuppressant therapy
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.